Details

Autor(en) / Beteiligte

• Han, Di
• He, Xiao‐Yan
• Huang, Yun
• Gao, Min
• Guo, Tao
• Ren, Xiao‐He
• Liao, Xin‐Ru
• Chen, Xue‐Si
• Pang, Xuan
• Cheng, Si‐Xue

Titel

A Multifunctional Delivery System for Remodulating Cell Behaviors of Circulating Malignant Cells to Prevent Cell Fusion

Ist Teil von

• Advanced science, 2023-10, Vol.10 (29), p.e2303309-n/a

Ort / Verlag

Weinheim: John Wiley & Sons, Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Cell fusion plays a critical role in cancer progression and metastasis. However, effective modulation of the cell fusion behavior and timely evaluation on the cell fusion to provide accurate information for personalized therapy are facing challenges. Here, it demonstrates that the cancer cell fusion behavior can be efficiently modulated and precisely detected through employing a multifunctional delivery vector to realize cancer targeting delivery of a genome editing plasmid and a molecular beacon‐based AND logic gate. The multifunctional delivery vector decorated by AS1411 conjugated hyaluronic acid and NLS‐GE11 peptide conjugated hyaluronic acid can specifically target circulating malignant cells (CMCs) of cancer patients to deliver the genome editing plasmid for epidermal growth factor receptor (EGFR) knockout. The cell fusion between CMCs and endothelial cells can be detected by the AND logic gate delivered by the multifunctional vector. After EGFR knockout, the edited CMCs exhibit dramatically inhibited cell fusion capability, while unedited CMCs can easily fuse with human umbilical vein endothelial cells (HUVEC) to form hybrid cells. This study provides a new therapeutic strategy for preventing cancer progression and a reliable tool for evaluating cancer cell fusion for precise personalized therapy. Using a multifunctional delivery vector, the genome editing plasmid can be specifically delivered into circulating malignant cells in whole blood from cancer patients for robust epidermal growth factor receptor (EGFR) knockout to effectively block cancer cell fusion. This study not only demonstrates a new therapeutic strategy to prevent cancer progression through remodulating malignant cell behaviors but also provides a reliable tool for evaluating cancer cell fusion.